Literature DB >> 28222941

Diabetes and lifetime risk of stroke and subtypes in an urban middle-aged population.

Tanvir Chowdhury Turin1, Tomonori Okamura2, Nahid Rumana3, Arfan Raheen Afzal4, Makoto Watanabe5, Aya Higashiyama6, Yoko M Nakao7, Michikazu Nakai8, Misa Takegami6, Kunihiro Nishimura9, Yoshihiro Kokubo5, Akira Okayama10, Yoshihiro Miyamoto11.   

Abstract

AIMS: Lifetime risk (LTR) is defined as the cumulative probability of developing a disease in one's remaining lifetime from a given index age. The impact of diabetes on the LTR of stroke events in Asians, where stroke incidence is higher than for Westerners, has not been estimated yet. These estimates can be useful for diabetes knowledge translation activities.
METHODS: All participants who were stroke-free at baseline in the Suita Study, a cohort study of cardiovascular diseases in Japan, were included in the study sample. Age, in years, was used as the time-scale. Age-specific incidence rates were calculated using the person-years method within five-year bands. We estimated the sex- and index-age-specific LTR of first-ever stroke accounting for the competing risk of death.
RESULTS: In this cohort study, we followed 5515 participants from 1989 to 2007 for 71,374.23 person-years. At age 40, the LTRs, adjusted for competing risk of death, for all strokes were 15.98% for men without diabetes and 26.64% for men with diabetes. The LTR for stroke was 10.66% higher for men with diabetes than men without diabetes. For women of same index age, the LTR of stroke was 17.29% and 30.72% with diabetes and without diabetes, respectively. The difference in LTR between persons with diabetes and without diabetes was 13.43%. This increased LTR of strokes for persons with diabetes was observed among both men and women across all index ages. Similar results were observed for cerebral infarction stroke subtype.
CONCLUSIONS: In this urban community-based population we observed that diabetes has a significant effect on the residual LTR of stroke for both men and women of middle age. This knowledge can be used to inform public health education and planning.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cohort; Diabetes; Japan; Lifetime risk; Stroke

Mesh:

Year:  2017        PMID: 28222941     DOI: 10.1016/j.jdiacomp.2017.02.002

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  4 in total

1.  Impact of hypertension stratified by diabetes on the lifetime risk of cardiovascular disease mortality in Japan: a pooled analysis of data from the Evidence for Cardiovascular Prevention from Observational Cohorts in Japan study.

Authors:  Yukiko Imai; Takumi Hirata; Shigeyuki Saitoh; Toshiharu Ninomiya; Yoshihiro Miyamoto; Hirofumi Ohnishi; Yoshitaka Murakami; Hiroyasu Iso; Sachiko Tanaka; Katsuyuki Miura; Akiko Tamakoshi; Michiko Yamada; Masahiko Kiyama; Hirotsugu Ueshima; Shizukiyo Ishikawa; Tomonori Okamura
Journal:  Hypertens Res       Date:  2020-07-03       Impact factor: 3.872

2.  Development and validation of risk prediction models for stroke and mortality among patients with type 2 diabetes in northern China.

Authors:  X Shao; H Liu; F Hou; Y Bai; Z Cui; Y Lin; X Jiang; P Bai; Y Wang; Y Zhang; C Lu; H Liu; S Zhou; P Yu
Journal:  J Endocrinol Invest       Date:  2022-08-16       Impact factor: 5.467

3.  Longitudinal Trajectories of Fasting Plasma Glucose and Risks of Cardiovascular Diseases in Middle Age to Elderly People Within the General Japanese Population: The Suita Study.

Authors:  Soshiro Ogata; Makoto Watanabe; Yoshihiro Kokubo; Aya Higashiyama; Yoko M Nakao; Misa Takegami; Kunihiro Nishimura; Michikazu Nakai; Eri Kiyoshige; Kiminori Hosoda; Tomonori Okamura; Yoshihiro Miyamoto
Journal:  J Am Heart Assoc       Date:  2019-02-05       Impact factor: 5.501

4.  Longitudinal changes in fasting plasma glucose are associated with risk of cancer mortality: A Chinese cohort study.

Authors:  Mengyin Wu; Jieming Lu; Zongming Yang; Peng Shen; Zhebin Yu; Mengling Tang; Mingjuan Jin; Hongbo Lin; Kun Chen; Jianbing Wang
Journal:  Cancer Med       Date:  2021-06-21       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.